SCHEMBL7799603

SCHEMBL7799603

CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccc(C)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 15/20 0.81
ESR2 Q92731 6/20 0.81
ESRRG P62508 6/20 0.81
MAPT P10636 3/20 0.81
CYP3A4 P08684 3/20 0.81
ESRRB O95718 3/20 0.81
MEN1 O00255 2/20 0.81
TP53 P04637 2/20 0.81
KMT2A Q03164 2/20 0.81
PGR P06401 2/20 0.81
KDM4E B2RXH2 1/20 0.81
ALDH1A1 P00352 1/20 0.81
LMNA P02545 1/20 0.81
HIF1A Q16665 1/20 0.81
NPSR1 Q6W5P4 1/20 0.81
PLD2 O14939 1/20 0.81
PLD1 Q13393 1/20 0.81
HDAC6 Q9UBN7 5/20 0.73
CYP1A2 P05177 2/20 0.72
CYP2D6 P10635 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10827999 1.00 ESR1 (0.81) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL10828052 1.00 ESR1 (0.81) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL9857240 0.95 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL9857837 0.95 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL9857247 0.95 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL15668666 0.90 ESR1 (1.00) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL16575061 0.90 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL2615530 0.90 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
SCHEMBL5320201 0.90 ESR1 (0.90) ESR1ESR2ESRRGMAPTCYP3A4
Afimoxifene SCHEMBL9189 0.90 ESR1 (1.00) ESR1ESR2ESRRGMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0002097-A1 Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-05-30 EP claimed
US-20010041745-A1 Methods for increasing levels of acetylcholine ELI LILLY & COMPANY 2001-11-15 US disclosed
US-4623660-A ANTIESTROGENS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-18 US disclosed
US-4623660-A ANTIESTROGENS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-18 US disclosed
EP-0002097-B1 TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-08-05 EP disclosed
EP-0002097-A1 Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-05-30 EP disclosed
EP-0002097-A1 Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041745-A1 Methods for increasing levels of acetylcholine ACHE, CHRNB1, CHRNA1 ESR1 3253/4885ESR2 1376/4885ESRRG 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.